Lingohr-Smith M - Search Results

1

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.

Dhamane AD, Baker CL, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Dhamane AD, et al. Curr Med Res Opin. 2019 Oct;35(10):1769-1776. doi: 10.1080/03007995.2019.1623187. Epub 2019 Jun 5. Curr Med Res Opin. 2019. PMID: 31120309

2

Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.

Lin J, Lingohr-Smith M, Kwong WJ. Lin J, et al. J Manag Care Pharm. 2014 Feb;20(2):174-86. doi: 10.18553/jmcp.2014.20.2.174. J Manag Care Pharm. 2014. PMID: 24456319 Free PMC article.

3

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.

Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Amin A, et al. J Med Econ. 2014 Nov;17(11):763-70. doi: 10.3111/13696998.2014.950670. Epub 2014 Aug 12. J Med Econ. 2014. PMID: 25078794 Free article.

4

Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results.

Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Amin A, et al. J Thromb Thrombolysis. 2015 Aug;40(2):131-8. doi: 10.1007/s11239-014-1158-2. J Thromb Thrombolysis. 2015. PMID: 25502587

5

Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Amin A, et al. J Med Econ. 2015 Jun;18(6):399-409. doi: 10.3111/13696998.2015.1007210. Epub 2015 Feb 9. J Med Econ. 2015. PMID: 25586203 Free article.

6

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ. Joshi K, et al. J Med Econ. 2015;18(8):629-36. doi: 10.3111/13696998.2015.1033424. Epub 2015 Apr 22. J Med Econ. 2015. PMID: 25800457 Free article. Clinical Trial.

7

Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Amin A, et al. Clin Appl Thromb Hemost. 2016 Jan;22(1):5-11. doi: 10.1177/1076029615585991. Epub 2015 May 19. Clin Appl Thromb Hemost. 2016. PMID: 25993994 Free article. Review.

8

Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.

Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Amin A, et al. J Manag Care Spec Pharm. 2015 Oct;21(10):965-72. doi: 10.18553/jmcp.2015.21.10.965. J Manag Care Spec Pharm. 2015. PMID: 26402395 Free PMC article.

9

Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.

Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Singh P, Lin J. Deitelzweig S, et al. Curr Med Res Opin. 2016;32(1):87-94. doi: 10.1185/03007995.2015.1103217. Epub 2015 Nov 2. Curr Med Res Opin. 2016. PMID: 26451675

10

DOES CLINICAL INERTIA VARY BY PERSONALIZED A1C GOAL? A STUDY OF PREDICTORS AND PREVALENCE OF CLINICAL INERTIA IN A U.S. MANAGED-CARE SETTING.

Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P. Lin J, et al. Endocr Pract. 2016 Feb;22(2):151-61. doi: 10.4158/EP15868.OR. Epub 2015 Oct 22. Endocr Pract. 2016. PMID: 26492540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters